EOS Imagine raises over €38m on NYSE

20 February 2012

Your browser does not support inline frames or is currently configured not to display inline frames. NBGI Ventures, the specialist investment arm of NBGI Private Equity, has announced that its portfolio company EOS Imagine, has raised over €38 million in a successful and heavily oversubscribed public offering of shares on the NYSE Euronext. EOS Imagine has developed the world’s first 3D full-view, weight-bearing orthopaedic imaging system.

Based on the opening trade price, the company is valued at approximately €120 million, reflecting substantial value creation since NBGI Ventures’ original investment in 2007.

The success of the IPO confirms EOS Imagine’s outstanding technology pedigree, its sound commercial and clinical proposition and its potential for strong commercial growth on a global level.
Aris Constantinides, Investment Director of NBGI Ventures, stated: “At the time we first invested in the Company, we recognised the potential to create a global business. Since then, we have made a significant contribution to the business operationally, including introducing its current Chairman, Stephane Sallmard, and in working closely with management in developing its commercial model. The successful IPO now positions EOS Imagine for the next stage of its development.”

Stephane Sallmard added: “The quality and energy of CEO Marie Meynadier and her team, as well as the continuous support of NBGI Ventures and our other investors, have been crucial to the growth of the business and to the achievement of the IPO.”

The success of the EOS Imagine IPO follows two other significant recent developments in the NBGI Ventures portfolio. Last month Reverse Medical announced the sale of its access catheter lines businesses to Covidien, the proceeds of which generated a substantial return to its investors and will contribute to the future growth of the business. In addition, Technolas Perfect Vision recently entered into a definitive agreement providing Bausch & Lomb with an option to purchase the company for a total value of up to €450 million, based on the achievement of certain milestones and earnouts.

Aris Constantinides concluded: “We are very pleased to have commenced 2012 with these promising transactions and I hope the year ahead will see further milestones being met by our portfolio and the companies within it.”

	EOS Imagine raises over €38m on NYSE 20 February 2012 Your browser does not support inline frames or is currently configured not to display inline frames. NBGI Ventures, the specialist investment arm of NBGI Private Equity, has announced that its portfolio company EOS Imagine, has raised over €38 million in a successful and heavily oversubscribed public offering of shares on the NYSE Euronext. EOS Imagine has developed the world’s first 3D full-view, weight-bearing orthopaedic imaging system. Based on the opening trade price, the company is valued at approximately €120 million, reflecting substantial value creation since NBGI Ventures’ original investment in 2007. The success of the IPO confirms EOS Imagine’s outstanding technology pedigree, its sound commercial and clinical proposition and its potential for strong commercial growth on a global level. Aris Constantinides, Investment Director of NBGI Ventures, stated: “At the time we first invested in the Company, we recognised the potential to create a global business. Since then, we have made a significant contribution to the business operationally, including introducing its current Chairman, Stephane Sallmard, and in working closely with management in developing its commercial model. The successful IPO now positions EOS Imagine for the next stage of its development.” Stephane Sallmard added: “The quality and energy of CEO Marie Meynadier and her team, as well as the continuous support of NBGI Ventures and our other investors, have been crucial to the growth of the business and to the achievement of the IPO.” The success of the EOS Imagine IPO follows two other significant recent developments in the NBGI Ventures portfolio. Last month Reverse Medical announced the sale of its access catheter lines businesses to Covidien, the proceeds of which generated a substantial return to its investors and will contribute to the future growth of the business. In addition, Technolas Perfect Vision recently entered into a definitive agreement providing Bausch & Lomb with an option to purchase the company for a total value of up to €450 million, based on the achievement of certain milestones and earnouts. Aris Constantinides concluded: “We are very pleased to have commenced 2012 with these promising transactions and I hope the year ahead will see further milestones being met by our portfolio and the companies within it.” To top